Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

BACKGROUND: Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer. METHODS: All serious adverse events that...

Descrición completa

Detalles Bibliográficos
Main Authors: Kerr, D, Dunn, J, Langman, M, Smith, J, Midgley, R, Stanley, A, Stokes, J, Julier, P, Iveson, C, Duvvuri, R, McConkey, C
Formato: Journal article
Idioma:English
Publicado: 2007

Títulos similares

Títulos similares